Belpointe Asset Management’s Kalaris Therapeutics KLRS Stock Holding History
Bought
Maintained
Sold
Other funds holding KLRS
SL
WT
Belpointe Asset Management's KLRS Position: Q3 2026 in Review
Belpointe Asset Management held its Kalaris Therapeutics (KLRS) position steady in Q3 2026 at 40,000 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #1125.
Belpointe Asset Management first reported a position in KLRS in Q3 2025 and has held it in 5 quarters since. The position peaked at $338K in Q4 2025. 53 funds tracked by Wall St. Rank hold KLRS as of Q3 2026.
- Belpointe Asset Management held 40,000 shares of Kalaris Therapeutics worth $116K as of Q3 2026.
- Belpointe Asset Management left its Kalaris Therapeutics share count unchanged in Q3 2026.
- Kalaris Therapeutics made up ﹤0.01% of Belpointe Asset Management's portfolio in Q3 2026, its #1125 holding.
- Belpointe Asset Management first reported a position in Kalaris Therapeutics in Q3 2025 and has held it in 5 quarters since.
- Belpointe Asset Management's Kalaris Therapeutics position peaked at $338K in Q4 2025.
- 53 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2026.
Based on Belpointe Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.